Srinivasan Jayakumar
Srinivasan Jayakumar has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Christopher L. Cioffi
Department of Chemistry and Chemical Biology, Rensselaer Polytechnic Institute, Troy, USA
2 shared publications - Gaddam Mahesh
Department of Chemistry and Chemical Biology
2 shared publications - Irina Lotsaris
School of Medical Sciences, University of Sydney, Sydney, Australia
2 shared publications Jay Mulmule
Department of Chemistry and Chemical Biology
2 shared publicationsJulian Peiser-Oliver
Molecular and Cellular Biomedicine Theme, School of Medical Sciences
2 shared publicationsKrishna Suleria
Department of Chemistry and Chemical Biology
2 shared publications
Latest Publications
- 15 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10278-10314
Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain
Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2–/–) mice. To address these challenges, we developed a series of second-generation, conformationally restricted indoline analogues that act as noncompetitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, nonopioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.
- 15 April 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (9) , 10278-10314
Identification of Non-competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-opioid Therapeutic Strategy for Neuropathic Pain
Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2–/–) mice. To address these challenges, we developed a series of second-generation, conformationally restricted indoline analogues that act as noncompetitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, nonopioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.
- 10 February 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (3) , 545-552
Bioresponsive MR Imaging Probes for Noninvasive Monitoring of AAV Gene Therapy
Gene therapy has emerged as a powerful approach for treating diverse diseases, including genetic disorders, retinal diseases, and certain cancers. Real-time, noninvasive in vivo tracking of gene expression is essential for evaluating therapeutic efficacy. β-galactosidase (β-gal), a hydrolase encoded by the Escherichia coli lacZ gene or the human GLB1 gene, is widely used as a reporter of gene expression. In humans, β-gal deficiency underlies several fatal neurodegenerative disorders, including GM1 gangliosidosis. Here, we report the development of a β-gal-activated, human serum albumin (HSA)-binding gadolinium(III)-based MR contrast agent for noninvasive assessment of adeno-associated virus (AAV) gene therapy in GM1 gangliosidosis mice. The probe exhibited a gradual increase in MR relaxation rate upon incubation with β-gal in the presence of 4.5% HSA. Following intravenous administration, AAV-treated GM1 mice demonstrated distinct MR signal enhancement and kinetic profiles compared to untreated β-gal-deficient controls. This study establishes an enzyme-activated, protein-binding MR imaging strategy for real-time, noninvasive monitoring of AAV gene therapy.
- 10 February 2026
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 37 (3) , 545-552
Bioresponsive MR Imaging Probes for Noninvasive Monitoring of AAV Gene Therapy
Gene therapy has emerged as a powerful approach for treating diverse diseases, including genetic disorders, retinal diseases, and certain cancers. Real-time, noninvasive in vivo tracking of gene expression is essential for evaluating therapeutic efficacy. β-galactosidase (β-gal), a hydrolase encoded by the Escherichia coli lacZ gene or the human GLB1 gene, is widely used as a reporter of gene expression. In humans, β-gal deficiency underlies several fatal neurodegenerative disorders, including GM1 gangliosidosis. Here, we report the development of a β-gal-activated, human serum albumin (HSA)-binding gadolinium(III)-based MR contrast agent for noninvasive assessment of adeno-associated virus (AAV) gene therapy in GM1 gangliosidosis mice. The probe exhibited a gradual increase in MR relaxation rate upon incubation with β-gal in the presence of 4.5% HSA. Following intravenous administration, AAV-treated GM1 mice demonstrated distinct MR signal enhancement and kinetic profiles compared to untreated β-gal-deficient controls. This study establishes an enzyme-activated, protein-binding MR imaging strategy for real-time, noninvasive monitoring of AAV gene therapy.
- Open Access
- 21 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Identification of Non-Competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-Opioid Therapeutic Strategy for Neuropathic Pain
Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2-/-) mice. To address these challenges, we developed a series of sec-generation, conformationally restricted indoline analogues that act as non-competitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, non-opioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.
- 21 November 2025
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessIdentification of Non-Competitive and Reversible Inhibitors of Glycine Transporter 2: A Promising Non-Opioid Therapeutic Strategy for Neuropathic Pain
Glycine transporter 2 (GlyT2) regulates extracellular glycine in the central nervous system (CNS) and is a promising target for restoring inhibitory neurotransmission in chronic pain. Although GlyT2 inhibitors show analgesic efficacy in rodent neuropathic pain models, the prototypical inhibitor ORG25543 (1) is limited by poor pharmacological properties, including slow dissociation kinetics and neuromotor toxicity at therapeutic doses, recapitulating the phenotype of homozygous GlyT2 knockout (GlyT2-/-) mice. To address these challenges, we developed a series of sec-generation, conformationally restricted indoline analogues that act as non-competitive and reversible GlyT2 inhibitors with varied potency and recovery kinetics. Among them, RPI-GLYT2-82 produced effective analgesia in murine neuropathic pain models without inducing excitatory neuromotor side effects observed with ORG25543. Collectively, these findings underscore the translational potential of reversible GlyT2 inhibitors as safe, non-opioid therapeutics for the management of neuropathic pain and provide a foundation for continued optimization of this chemotype toward preclinical candidate selection.
- 1 January 2003
- Published by Elsevier
- p. 84
Synthetic and medicinal applications of imidazoline scaffolds
- 1 January 2003
- Published by Elsevier
- p. 84
Synthetic and medicinal applications of imidazoline scaffolds